Washington, April 30: Indian Ambassador to the US, Taranjit Singh Sandhu on Thursday (local time) met with Pfizer CEO Albert Bouria to discuss ways in which the COVID-19 vaccine maker can support healthcare efforts in India.

Taking to Twitter, Sandhu said he discussed with the Pfizer CEO on how the company can also strengthen the pandemic response in India, which is in the grisp of a devastating second wave of COVID-19. No COVID-19 Vaccination in Mumbai for Next 3-Days Due to Unavailability of Vaccine Stock, Says BMC.

"Important conversation with @AlbertBourla CEO @pfizer today evening. Discussed ways in which Pfizer could support healthcare efforts incl vaccines in India, and strengthen our pandemic response," he tweeted.

Moderna and Pfizer-BioNTech COVID-19 vaccines are the first two coronavirus vaccines authorised by the Food and Drug Administration (FDA) for emergency use and already have been given to millions of Americans.

Bourla had recently said that an oral drug for treating coronavirus could be ready next year, adding the company is working on two antivirals -- an oral and an injectable.

Meanwhile, the Drug Controller General of India (DCGI) approved the use of the Russian Sputnik V vaccine against coronavirus in the country on April 12. Now, India has three vaccinesCovishield, Covaxin and Sputnik V for its inoculation program against COVID-19.

India started its vaccination drive on January 16 with priority given to all healthcare and frontline workers in the first phase. The second phase started on March 1 where doses were administered to people above the age of 60 and those between 45 and 59 years with specific comorbidities.

The third phase of COVID-19 vaccination drive will start from May 1 wherein all above 18 years of age will be eligible for inoculation.

(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)